The two-day conference at Stanford will bring together experts from academia, industry and government to discuss drug policy, research and business opportunities.
February 21, 2018
Registration is open for the 2018 Stanford Drug Discovery Conference, which will take place April 23-24 at the medical school’s Li Ka Shing Center for Learning and Knowledge.
The conference will bring together experts in drug discovery to discuss a broad range of policy, research and business opportunities. Speakers will include leaders in drug discovery from academia, industry and government.
A lifetime achievement award will be presented to Roy Vagelos, MD, chair of Regeneron Pharmaceuticals Inc.
Multiple representatives from biotechnology and pharmaceutical companies will be speaking during a session titled “View From the Top,” including Ken Frazier, CEO of Merck; Bob Bradway, CEO of Amgen; and Joseph Jimenez, former CEO of Novartis.
“The Drug Discovery Symposium will be a unique opportunity for Stanford trainees and faculty to network with pioneers in translational research, gain insight into new opportunities from federal and foundation policymakers, and learn from the experiences of corporate leaders in the pharmaceutical industry,” said Joseph Wu, MD, PhD, professor of medicine and director of the Stanford Cardiovascular Institute.
Applications are being accepted for translation-stage projects to be presented “Shark Tank”-style to a panel of scientists, CEOs and entrepreneurs.
Admission to the conference for academics is $50. For others, it’s $250. Registration is available online.
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.
